Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 30Ganglioneuroblastoma 7Osteosarcoma 3Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Neoplasms 1Neoplasm, Residual 1Medulloblastoma 1Glioma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Temozolomide 8Irinotecan 7Melphalan 6Cyclophosphamide 6X-Rays 5Topotecan 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Granulocyte Colony-Stimulating Factor 5Specimen Handling 4Nuclear Medicine Department, Hospital 4Busulfan 4palbociclib 3fludarabine 3Vincristine 3Thiotepa 3Stem Cell Transplantation 3Sirolimus 3Nivolumab 3Etoposide 3Bone Marrow Transplantation 3Biopsy 3ulixertinib 2tipifarnib 2thymoglobulin 2tazemetostat 2selpercatinib 2omburtamab I-131 2olaparib 2larotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × dinutuximab × CNS × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡